Research Comparison
Retatrutide (GLP-3) vs Semaglutide
Retatrutide (GLP-3) and Semaglutide are often compared because both sit in metabolic research. Retatrutide (GLP-3) acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research, while Semaglutide acts on GLP-1 (mono agonist) and is studied for metabolic & body-weight research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.
Retatrutide (GLP-3)
Metabolic
Semaglutide
Metabolic
Frequently asked
- What is the difference between Retatrutide (GLP-3) and Semaglutide?
- The main difference is mechanism and research stage. Retatrutide (GLP-3) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Semaglutide targets GLP-1 (mono agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.
- Are Retatrutide (GLP-3) and Semaglutide approved for human use?
- No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — Retatrutide (GLP-3): phase 3 (investigational); Semaglutide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
- How is purity verified for Retatrutide (GLP-3) and Semaglutide?
- Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.
Related comparisons
Build a multi-compound set in the Stack Builder or run the reconstitution calculator.
Research references
Primary literature for Retatrutide (GLP-3) and Semaglutide. Provided for scientific context only — not medical or dosing guidance.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315 →
- Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280 →
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185 →
- Amaro A, et al. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022. PMID 36691308 →
Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.